Press Room

When you have kidney cancer...

02/21/2018

There's one important thing to remember, when you've been diagnosed with kidney cancer. What is it?

Videos:2017 Kidney Cancer Association Patient & Survivor Conference

01/09/2018

Videos from KCA patient and survivor conference that held in North Carolina on December 9th, 2017 is now available online: Welcome and Introduction to the Kidney Cancer Association/ Genetics of RCC: Is my family at risk?/ Advances in the Surgical Treatment of RCC/ Adjuvant treatment of RCC/ Sequencing therapies for metastatic RCC/ Use of Immunotherapy in RCC/ Recent clinical trial advances in RCC/ Integrating early palliative care in RCC management/ Managing the side effects of RCC treatment/ Panel for Questions and Conclusions.

FDA Grants Breakthrough Designation for Avelumab in Combination with INLYTA in Advanced Renal Cell Carcinoma

01/02/2018

"A combination approach with an immunotherapy, whose activity may complement existing agents such as INLYTA, has the potential to improve outcomes for patients with advanced renal cancer..."

FDA Approves Adjuvant Sunitinib for High-Risk RCC

12/31/2017

The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.

U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma

12/19/2017

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults.

NICE recommends Eisai’s Kisplyx for renal cell carcinoma

12/14/2017

Eisai Oncology business group EMEA chairman and CEO Gary Hendler said: “We are delighted that NICE is recommending lenvatinib in combination with everolimus for routine access to adult patients for the treatment of advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

Phase III IMmotion151 Study Met Co-primary Goal In Kidney Cancer

12/12/2017

The study demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death...

Dr. Escudier: The Future of RCC Treatment

12/07/2017

Bernard Escudier, M.D., is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, France. Dr. Escudier’s research focuses on renal cell carcinoma, immunotherapy and on development of new therapeutic strategies.

“I need to go to the doctor,” Quiet 5-year-old girl knew something was wrong

12/06/2017

Reese Park is working toward a day with no training wheels outside her Bridge Creek home. The 5-year-old is biking with her siblings, which includes quite a crew since she's the second oldest of six children. Reese's parents describe her as strong and quiet, so she seemed very out of character last July when she told her dad she needed medical help right away.

Preoperative Cholesterol Level Is Associated With Worse Pathological Outcomes

12/06/2017

Lipid metabolism has been suggested to be associated with clinical outcomes of renal cell carcinoma (RCC). In this study, we aimed to investigate the relationship between preoperative cholesterol level (PCL) and postoperative outcomes of patients with localized RCC.

  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93  |  94  |  95  |  96  |  97  |  98  |  99  |  100  |  101  |  102  |  103  |  104  |  105  |  106  |  107  |  108  |  109  |  110  |  111  |  112  |  113  |  114  |  115  |  116  |  117  |  118  |  119  |  120  |  121  |  122  |  123  |  124  |  125  |  126  |  127  |  128  |  129  |  130  |  131  |  132  |  133  |  134  |  135  |  136  |  137  |  138  |  139  |  140  |  141  |  142  |  143  |  144  |  145  |  146  |  147  |  148  |  149  |  150  |  151  |  152  |  153  |  154  |  155  |  156  |  157  |  158  |  159  |  160  |  161  |  162  |  163  |  164  |  165  |  166  |  167  |  168  |  169  |  170  |  171  |  172  |  173  |  174  |  175  |  176  |  177  |  178  |  179  |  180  |  181  |  182  |  183  |  184  |  185  |  186  |  187  |  188  |  189  |  190  |  191  |  192  |  193  |  194  |  195  |  196  |  197  |  198  |  199  |  200  |  201  |  202  |  203  |  204  |  205  |  206  |  207  |  208  |  209  |  210  |  211  |  212  |  213  |  214  |  215  |  216  |  217  |  218  |  219  |  220  |  221  |  222  |  223  |  224  |  225  |  226  |  227  |  228  |  229  |  230  |  231  |  232  |  233  |  234  |  235  |  236  |  237  |  238  |  239  |  240  |  241  |  242  |  243  |  244  |  245  |  246  |  247  |  248  |  249  |  250  |  251  |  252  |  253  |  254  |  255  |  256  |  257  |  258  |  259  |  260  |  261  |  262  |  263  |  264  |  265  |  266  |  267  |  268  |  269  |  270  |  271  |  272  |  273  |  274  |  275  |  276  |  277  |  278  |  279  |  280  |  281  |  282  |  283  |  284  |  285  |  286  |  287  |  288  |  289  |  290  |  291  |  292  |  293  |  294  |  295  |  296  |  297  |  298  |  299  |  300  |  301  |  302  |  303  |  304  |  305  |  306  |  307  |  308  |  309  |  310  |  311  |  312  |  313  |  314  |  315  |  316  |  317  |  318  |  319  |  320  |  321  |  322  |  323  |  324  |  325  |  326  |  327  |  328  |  329  |  330  |  331  |  332  |  333  |  334  |  335  |  336  |  337  |  338  |  339  |  340  |  341  |  342  |  Next
Powered by NeonCRM